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Background: Dengue is the most frequent arthropod-borne viral disease worldwide. Because dengue manifestations
are similar to those of many other febrile syndromes, the availability of dengue-specific laboratory tests is useful for the
differential diagnosis. Timely and accurate diagnosis of dengue virus (DENV) infection is important for appropriate
management of complications, pathophysiological studies, epidemiological investigations and optimization of
vector-control measures. Several “in-house” reverse transcriptase-polymerase chain reaction (RT-PCR) methods
have been developed to detect, type and/or quantify DENV. Standardized dengue RT-PCR kits with internal
controls have been recently introduced, but need clinical evaluation. We assessed the performances of 4 commercial
DENV real-time RT-PCR kits.
Findings: The 4 kits were evaluated using a panel of 162 samples positive with an existing in-place hemi-nested
RT-PCR used for routine DENV-infection diagnosis in patients with acute-febrile disease. The panel included 46
DENV-1, 37 DENV-2, 33 DENV-3, and 46 DENV-4. Also, 70 negative serum specimens were used to determine
specificity. Geno-Sen’s Dengue 1–4 Real-Time RT-PCR kit was the only assay to provide quantification using
standards, but lacked sensitivity for DENV-4 detection. The SimplexaTM Dengue RT-PCR assay, with 151 (93.2%
[95% confidence interval, 89.3–97.1]) positive samples, had significantly higher sensitivity than the other 3 kits; in
a complementary evaluation of 111 consecutive patients’ samples, its performance and genotyping agreed with
the hemi-nested gold-standard assay.
Conclusions: The SimplexaTM Dengue RT-PCR’s good performance to detect and genotype DENV1–4 requires further
evaluation in multicenter and prospective studies, particularly in settings of clinical diagnosis during dengue outbreaks.
Keywords: Dengue, Diagnosis, Real-time polymerase chain reaction, RT (reverse transcription)-PCR, Genotype,
Quantification, Commercial assaysFindings
Dengue is caused by 4 related viruses, (DENV)-1, −2, −3
and −4, and is the most common and widespread
arthropod-borne viral disease in the world. This self-
limited infection can be asymptomatic or cause a clinical
spectrum ranging from mild fever (DF) to severe, life-
threatening illness, dengue hemorrhagic fever (DHF) and
dengue shock syndrome (DSS). Other severe manifesta-
tions, including hepatitis, myocarditis or encephalitis, may
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unless otherwise stated.dengue symptoms are similar to those of many other un-
differentiated febrile syndromes, new commercial tests that
can be used for case management have to be clinically eval-
uated. Laboratory-based surveillance is also of importance
for early warning of dengue outbreaks and optimization of
vector-control measures [2].
Current diagnostic methods have limitations. Enzyme-
linked immunosorbent assays to detect immunoglobulin
M are used by most laboratories, but that response is
absent early during the disease course and may remain un-
detectable in secondary dengue. DENV-NS1 antigen can
be detected during the first few days of fever. However, re-
cent evaluations of commercial NS1 assays have had lim-
ited sensitivity [3,4]. Virus isolation from acute-phase seraral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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are needed to obtain final results. Molecular methods
yield same- or next-day detection of DENV in acute-
phase serum or plasma. The 2-step hemi-nested reverse
transcriptase-polymerase chain reaction (RT-PCR) proto-
col, originally reported by Lanciotti et al. [5] and later
modified to a single-step multiplex RT-PCR [6], has
proved to be highly sensitive [7], and is used worldwide.
Conventional RT-PCR is being progressively replaced by
real-time RT-PCR, which limits the risks of carryover con-
tamination and is suitable for DENV-genome detection.
Another advantage of real-time RT-PCR is that it yields
reliable quantification, making it a useful tool for patho-
physiological studies. Almost all of the reported RT-PCR
methods are “in-house” procedures [8-29]. International
external quality studies have highlighted sensitivity and
specificity heterogeneities, even inter-laboratory using the
same method [30].
Levi et al. [31] evaluated a commercial real-time RT-PCR
kit (RealArt; artus/Qiagen, Germany) and found high agree-
ment with an in-house multiplex RT-PCR, but the test was
limited to DENV-3, and occasionally DENV-2, samples.
More recently, the US Food and Drug Administration
approved a Centers for Disease Control DENV-1–4 real-
time RT-PCR assay [32], but it has been shown to be less
sensitive than a laboratory-developed assay, particularly
for DENV-1 [33]. Herein, we evaluated the performances
of 4 recently developed commercial DENV real-time RT-
PCR kits.
The study was conducted in the Virology Laboratory,
where biological samples from patients with acute-febrile
syndromes are processed as follows: a 5 ml venous blood
sample, collected on the day of admission, is centrifuged,
and plasma or serum supernatant is divided into 2
aliquots, one stored at −4°C for daily RT-PCR and the
other frozen at −80°C until use. We analyzed 162
laboratory-confirmed stored samples collected during the
outbreaks that occurred the last decade: 46 DENV-1, 37
DENV-2, 33 DENV-3, and 46 DENV-4. A panel of 70
negative specimens was used to determine specificity. In
addition, we prospectively tested 111 samples from pa-
tients consecutively seen at the emergency unit for acute-
febrile syndromes at the peak of the 2010–2011 epidemic.
Because the study was non-interventional, e.g. with no
additional samplings or specific procedures for subjects,
no consent form from the patient was needed, as stated by
the French Public Health code. The consecutive samplings
were part of routine diagnosis. The dengue sample collec-
tion has been declared under the number DC-2009-979 to
the French ministry of health and the “Comité de protec-
tion des personnes Bordeaux sud-ouest/Outre-mer”,
according to the Bioethics laws (décret n°2007-1220 du
10 août 2007 relatif aux activités de prélèvement et
conservation à des fins scientifiques de collectionsd’échantillons biologiques). The dengue collection is
stored at the “Centre de Ressources Biologiques de la
Martinique” (CeRBiM). The CeRBiM database has been
agreed by the CNIL (“Commission nationale de l’infor-
matique et des libertés”).
RNA was extracted from 200 μL of stored aliquots using
NuCliSens EasyMag (bioMérieux, Craponne, France). All
samples were screened by hemi-nested RT-PCR with the
dengue virus consensus primers D1 and D2 and the
serotype-specific primers TS1, TS2, TS3, and TS4 [5].
Lanciotti’s protocol was adapted using the SuperScript
One-Step RT-PCR System with Platinum Taq DNA
Polymerase (Invitrogen, Life Technologies, France) [34].
Briefly, the first-round reaction was performed with
primers D1 and D2, 1 μl of SuperScript II RT/Platinum
Taq mix (Invitrogen), and 5 μl of the RNA template. The
second amplification was used forward primer D1 and
downstream primers TS1, TS2, TS3, and TS4, with the
TaqPCR Master Mix kit (Qiagen). Both the RT-PCR and
nested-PCR products were analyzed by gel electrophoresis
on a 2% agarose gel with ethidium bromide for ultraviolet
visualization. The expected size of the primary PCR
amplicons was 511 bp. Nested-PCR bands of 482, 119,
290, and 389 bp were considered specific for DENV-1,
DENV-2, DENV-3, and DENV-4, respectively. The
sensitivity of the assay has been previously evaluated to 1
PFU/ml with dengue virus titrated controls, and 1–10
molecules/reaction with dengue virus RNA standards
obtained by cloning the capsid-prM region into pCR4-
TOPO vector (data not shown). Finally, the procedure
was validated through participation in a multicenter
quality-control study conducted by the French National
Reference Center for Arboviruses (Institut de Recherche
Biologique des Armées, France).
Four commercial kits were evaluated versus Lanciotti’s
gold-standard protocol. All the commercial kits were fully
furnished, and were used according to the manufacturer’s
recommendations. The characteristics of the 4 kits tested
are summarized in Table 1.SimplexaTM dengue RT-PCR assay (Focus Diagnostics,
Cypress, CA)
The assay is based on bi-functional fluorescent-probe
primers and reverse primers amplifying DENV-1 NS5,
DENV-2 NS3, DENV-3 NS5, and DENV-4 capsid genes.
The Simplexa dengue 1-and-4–primer mix contains a
DENV-1–fluorescent 6-carboxyfluorescein (FAM) probe
and a DENV-4–CFR610 probe. The Simplexa dengue 2-
and-3–primer mix contains a DENV-3–FAM probe and
a DENV-2–CFR610 probe. Each primer mix includes a
Q670-labeled probe to detect the RNA internal control
(IC) used to monitor the extraction process and RT-PCR
inhibition. A positive control is provided in the kit.
Table 1 Characteristics of 4 commercial DENV real-time RT-PCR kits
Characteristic Geno-sen’s Liferiver Realstar Simplexa




Principle TaqMan TaqMan TaqMan TaqMan
Dye FAM FAM FAM FAM/CFR610
Internal control (dye) Yes (JOE) Yes (JOE) Yes (JOE) Yes (Q670)
PCR reactions, n 1 1 1 2
Genotyping No No No Yes
Quantitative Yes Yes No No
External standards 104–108 copies/mL 107 copies/mL Yes (not quantified) Yes (not quantified)
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Hamburg, Germany)
This assay is based on the amplification of DENV-specific
target sequences and target-specific probes labeled with
FAM reporter and quencher dyes. The probe specific to
the IC target is labeled with the fluorophore JOE. The IC
is added to the specimen/lysis buffer mixture. Primers and
probes, based on 2010 sequence alignments of all 4
DENV, detect but do not genotype them.
Dengue virus general type real-time RT-PCR kit LiferiverTM
(Shanghai ZJ Bio-Tech Co, China)
This kit contains a super mix for the specific amplification
of DENV-1–4 RNA. DENV amplicons are detected using
a probe carrying a FAM fluorophore and BHQ1 quencher.
The kit contains a system to identify possible RT-PCR
inhibition by measuring the VIC/JOE fluorescence of
the IC. The supplied external positive control, defined
as 1 × 107 copies/mL, enables determination of the gene
load.
Geno-Sen’s dengue 1–4 real-time RT-PCR kit (Genome
Diagnostics Pvt, New Delhi, India)
The specific master mix contains reagents and enzymes
for the specific amplification of DENV-1–4 and the
direct detection of the specific amplicon using the
TaqMan principle and FAM channel. An IC is providedTable 2 Sensitivities of commercial DENV real-time RT-PCR as
hemi-nested RT-PCR [5,34]
Serotype N Geno-sen’s (n (% [95% CI])
DENV-1 46 42 (91.3 [83.2–99.4])
DENV-2 37 33 (89.2 [79.2–99.2])
DENV-3 33 30 (90.9 [81.1–100])
DENV-4 46 33 (71.7 [58.7–84.8])
Total 162 138 (85.2 [79.7–90.7])to detect inhibitors in the extract. Five external positive
standards, range 104–108 copies/mL, are supplied for
determination of the gene load. The quantitation stan-
dards provided in the kit are treated in the same way as
extracted samples. This method was initially designed
for use in the Rotor Gene Thermocycler and we adapted
it to an ABI 7500 apparatus.
In accordance with conventional clinical pratice, amp-
lification and detection were performed in duplicate,
using an ABI Prism® 7500 (Applied Biosystems, France)
for LifeRiver, Real Star and GenoSen’s kits. For Simplexa,
we used the 3 M integrated cycler provided by Focus.
Negative and extraction controls were added at each
step to avoid contamination and eliminate inhibition.
The Liferiver kit had poor sensitivity on the initial
panel of 40 positive samples, detecting only 28 of
them, and was not further evaluated. The Geno-Sen’s,
RealStar and Simplexa kits were tested with a panel of
162 sera, and were positive for 138 (85.2%), 135
(83.3%), and 151 (93.2%), respectively (Table 2).
Simplexa sensitivity was significantly higher than those
of Geno-Sen’s (chi-square, P = 0.02) and RealStar kits
(P = 0.006). Simplexa sensitivities were homogeneous
(range 90.9%–95.6%) from one serotype to another.
For all positive samples, serotype identification was
concordant with Lanciotti’s hemi-nested round. Real-
Star achieved adequate sensitivity for DENV-3 andsays against a panel of clinical samples positive with
Realstar (n (% [95% CI]) Simplexa (n (% [95% CI])
36 (78.3 [66.3–90.2]) 44 (95.7 [89.7–100])
32 (86.5 [75.5–97.5]) 34 (91.9 [83.1–100])
30 (90.9 [81.1–100]) 30 (90.9 [81.1–100])
37 (80.4 [68.9–91.9]) 43 (93.5 [86.3–100])
135 (83.3 [77.6–89.1]) 151 (93.2 [89.3–97.1])
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DENV-1 and DENV-4 samples.
Geno-Sen’s was the only kit to provide quantification
using standards, with median virus loads of 5 × 107, 1 ×
107, 2 × 107 and 1 × 105 copies/mL, for DENV-1, −2, −3
and −4, respectively. We cannot exclude that the sampling
was biased towards higher loads, since it concerned symp-
tomatic patients. Viral loads were markedly lower for
DENV-4 samples. Notably, low DENV-4 loads in infections
were previously reported [17,24,35]. Using an in-house
quantification method during a DENV-1–DENV-4 co-
epidemic, we confirmed finding lower DENV-4 than
DENV-1 loads (data not shown). However, we cannot ex-
clude faulty DENV-4 amplification with Geno-Sen’s kit,
and its 71% detection rate is insufficient for clinical
diagnoses.
The analytical sensitivity of the Simplexa kit versus
Lanciotti’s procedure was also evaluated using dilu-
tions of DENV-1–4 strains. For all dilutions tested,
Simplexa assay sensitivity was similar to that of the
hemi-nested RT-PCR, with differences <0.5 log10. The
Simplexa kit was then tested prospectively on 111
successive patients’ samples. All samples positive with
the hemi-nested RT-PCR (3 DENV-1, 16 DENV-2, 6
DENV-4) were also positive with the Simplexa kit, with
cycle threshold below 31 cycles. One negative sample
with a cycle threshold of 38 was negative with both
methods after re-extraction.
Specificity was assessed using 70 samples negative with
Lanciotti’s RT-PCR. All were negative with Geno-Sen’s
and Simplexa kits, but 1 was weekly positive with RealStar.
Since no other flavivirus is known to circulate at signifi-
cant level in inhabitants of our Caribbean island [36], we
did not test for cross-reactivity with clinical specimens of
other member of the genus. West Nile virus lineage I and
II controls (AccuType, SeraCare, Life Sciences) were
checked negative with the Dengue Simplexa RT-PCR kit.
The recent outbreak of chikungunya did allow us to verify
the absence of cross-reactivity of the Dengue Simplexa
assay with this other arbovirus (data not shown). This is of
particular interest for countries threatened by its recent
emergence in the Americas. Another limitation of our
evaluation is the use of Caribbean DENV, which are only
representative of the Americas strains and not of DENV
circulating in other part of the world.
In summary, RT-PCR–based methods are widely
applied to obtain clinical diagnoses of infectious diseases,
and several in-house protocols have been evaluated for
DENV-RNA detection. Different reagent suppliers, reac-
tion conditions and technical skills may influence protocol
reproducibility from one laboratory to another. External
quality-assurance studies showed that differences in the
operational procedures led to discrepant results between
reference laboratories using the same in-house methods[30]. Commercial kits developed under good manufactur-
ing practices may offer improved reliability. They
correspond better to quality-insurance rules for clinical
diagnoses and include IC. Manufactured DENV RT-PCR
kits may provide broader access, and be less time-
consuming and more cost-effective for clinical diagnoses.
Our preliminary results showed good agreement between
the SimplexaTM Dengue RT-PCR assay and Lanciotti’s ref-
erence hemi-nested RT-PCR, currently used in our labora-
tory. That kit achieved >90% detection of each serotype,
with clinical samples obtained between days 1 and 7 after
fever onset, and concordance for genotyping. We think
that the combination of automated extraction and the
SimplexaTM RT-PCR kit should be evaluated in multicen-
ter and prospective studies in the context of clinical
management during dengue outbreaks.
Ethical Approval was not needed for this study, in line
with French regulations.
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